top of page
Near-term Pipeline
IMMvention's mission is to create a globally accessible therapy, benefiting patients with limited or no access to gene therapies. Currently in preclinical stage, IMM-4800 has exceptional drug-like properties differentiating it from other BACH1 inhibitors and positioning it for success.
Anticipated milestones include IND enabling studies and Phase 1 clinical trials in 2026/27. Followed by Phase 2/3 trials and FDA approval submission leading to a transformative solution for Sickle Cell Disease worldwide.

IMM–004 Systemic
Clinical Candidate
2026
IND
2026/27
Phase 1a/b
2026/27
Phase 2/3
TBD
Sickle Cell Disease (SCD)
Estimated Timelines
β-thal
PKD
Indication Expansion
Partnered with Novo Nordisk
Sickle C
Pipeline Programs
IMM–002 Systemic
IMM–005 CNS

bottom of page